Foster tapped as Creabilis CEO

Creabilis has appointed Eliot Forster as its new CEO. Creabilis release

Mersana Therapeutics has named Nicholas Bacopoulos as president and CEO. Bacopoulos succeeds Julie Olson, who has been appointed to the newly created role of chief technology officer. Mersana release

Calistoga Pharmaceuticals has tapped Andrew Guggenhime as chief financial officer. Calistoga release

InVivo Therapeutics has announced that Sean Moran has joined InVivo's management team as CFO. InVivo release

Glenn Kazo has become president of Prolong Pharmaceuticals. He succeeds Prolong founder Abraham Abuchowski, who remains CEO. Prolong release

Laureate Pharma has appointed Steven Johnson as VP, business development. Laureate release

OncoMethylome Sciences has named Melissa Thompson as VP regulatory affairs and quality assurance and Chris Thibodeau as VP commercial operations. OncoMethylome release

AAIPharma Services has appointed Tim Martin as executive VP of sales and marketing and Rob Goshert as VP of corporate accounts.  AAIPharma release

U.K.-based global clinical research organization ClinTec International has further established its U.S. presence with the appointment of a new executive VP, Dianne Kikta. ClinTec release

Tigris Pharmaceuticals has tapped Neil Flanzraich as executive chairman of the board of directors. Tigris release

Melior Discovery has appointed John Gruner as senior scientific fellow. Melior release

Carl Johnson has been appointed as the chairman of SCOLR Pharma's board of directors.  Johnson succeeds Michael Taglich, who will remain a member of the board. SCOLR release

Unigene Laboratories has announced the election of Joel Tune to its board of directors. Unigene release

Franklin Berger has been elected to Five Prime Therapeutics' board of directors. Five Prime release

Allosterix has announced the appointment of Professor Aharon Ciechanover, the Nobel Prize laureate; Dr. Avri Havron, Prolor Biotech CEO; Prof. Pnina Fishman, Can-Fite Biopharma CEO; and Prof. Mati Fridkin, peptide chemist expert, The Weizmann Institute, to its scientific advisory board. Allosterix release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.